Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of New York Mellon Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Bank of New York Mellon Corp trades at $160.35 (market cap $108.17B). The key difference: Bank of New York Mellon Corp is far larger — about 125.2× Amphastar Pharmaceuticals Inc's market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BNY | |
|---|---|---|
Market Cap | $863.95M | $108.17B |
Sector | Health | Financials |
52-Week High | $30.81 | $162.35 |
52-Week Low | $16.87 | $101.00 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
BNY trades at $157.65, down 0.75% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.46 exceeding expectations. Revenue and net income have shown steady growth, with 2025 revenue at $19.76 billion and net income at $5.55 billion. Recent news highlights BNY's expansion into digital transfer agency capabilities and a strategic collaboration with Galaxy Digital to advance digital asset infrastructure, signaling innovation in fund servicing.
The outlook for BNY is positive, supported by strong earnings performance, a consensus price target of $170.36, and a bullish analyst rating upgrade to Strong Buy by Zacks. Investment opportunities include continued revenue growth and margin expansion. Risks involve high investing cash outflows, competitive pressures in custody banking, and sensitivity to interest rate changes. The stock offers a dividend yield with recent increases, appealing to income-focused investors amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
